Report Code: A10525 | Pages: NA | Mar 2023 | 1121 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Parkinson’s Disease Market
Request Now !Parkinson’s Disease Market Outlook 2027
Parkinson's disease is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty in walking and talking. They may further experience mental &behavioral changes, sleep problems, depression, memory difficulties, and fatigue. Parkinson’s disease can be prevalent in both men and women. However, the disease affects about 50% more men than women. One clear risk factor for Parkinson's is age. Although most people with Parkinson’s first develop the disease at about age 60, about 5-10% of people with Parkinson's have "early-onset" disease, which begins before the age of 50. Early-onset forms of Parkinson's are often, but not always, inherited, and some forms have been linked to specific gene mutations.
Parkinson’s Disease Marketscope and structure analysis
Report Metric | Details |
Market size available for years | 2020–2027 |
Base year considered | 2019 |
Forecast period | 2021–2027 |
Forecast unit | Value (USD) |
Segments covered | Product, Route of Administration,and Region |
Regionscovered | North America (U.S. and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM), and the Middle East &Africa |
Companies covered | Abbvie Inc, Novartis AG, Schwarz Pharma, Acadia Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sunovion Pharmaceuticals, and Pharma Two B Ltd. |
COVID-19 scenarioanalysis
The major companies especially pharmaceutical and biotechnological came together with governments Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs such as hydroxychloroquine have seen huge boost in demand for the management of COVID-19. Increase in demand for drugs has been witnessed, which is likely to offer lucrative opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors:market scenario analysis, trends, drivers, and impact analysis
The major factor affecting the industry includesupsurge in the patient population.In addition, increase in geriatric population acts as a key growth driver of the global market, as aged individuals are highly susceptible to develop Parkinson’s disease.Furthermore, development of combination therapies for longer action of continuous dopaminergic stimulation drugs, neural transplantation, and gene therapy is expected to augment the market growth in the next coming years.
New product launches
Increase in focus over research and development such that the therapeutics become available to majority of population that are cost-efficient is expected to propel the Parkinson’s disease market growth in the coming years. For instance, in August 2019, FDA approved new add-on drug to treat off episodes in adults with Parkinson’s disease. The tablet named Nourianz (istradefylline) isas an add-on treatment to levodopa/carbidopa in adult patients with Parkinson’s disease experiencing "off" episodes. An "off" episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s diseasesymptoms, such as tremor and difficulty walking.
In April 2020, Neurocrine Biosciences, a San Diego-based medicine company, received Food and Drug Administration approval for a drug that makes a prominent Parkinson's disease treatment last longer. Patients in the U.S., though, wouldnot have access to the drug for at least another couple months, as Neurocrine intends to hold off any launch due to coronavirus-related concerns.
Surge in number of mergers and acquisitions
Increase in the number of mergers and acquisitions is anticipated toboost the industrygrowth in the coming years. For instance, in September 2020, Roche agreed to pay roughly $445 million for Inflazome, joining the race to introduce drugs that block the inflammasome, a part of the immune system linked to inflammatory diseases. The move will give the pharma company access to Inflazome’s entire pipeline, which includes two small molecules that have completed Phase I safety trials, Inzomelid and Somalix.
In October 2020, STADA Arzneimittel, the parent company of Thornton & Ross (T&R) and Reading-based Britannia Pharmaceuticals,strengthened its footprint in specialty pharmaceuticals by acquiring an innovative therapy used for treating late-stage Parkinson’s disease. The infusion of levodopa, carbidopa, and entacapone is already approved in Sweden, Denmark, Norway, and Finland, and STADA is currently submitting approval applications to launch the therapy in a number of major European markets. German-headquartered STADA is increasingly adding differentiated specialty pharmaceuticals to its existing strengths in generics and non-prescription consumer health products.
Key segments covered
Segments | Sub-segments |
Product |
|
Route of Administration |
|
Key benefits of the report:
Questions answered in the global Parkinson’s disease market research report:
Parkinson’s Disease Market Report Highlights
Aspects | Details |
---|---|
By Product |
|
By Route of Administration |
|
By Region |
|
Key Market Players | Abbvie Inc,, Novartis AG,, Schwarz Pharma,, Acadia Pharmaceuticals,, F. Hoffmann La Roche Ltd,, Sunovion Pharmaceuticals,, Pharma Two B Ltd, Medtronic Plc., AbbVie Inc., Boehringer Ingelheim GmbH |
Loading Table Of Content...
Start reading.
This Report and over 19,605+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers